Quince Therapeutics, Inc.
Income Statement
| Line Item | FY2018 |
|---|---|
| Revenue | — |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $10.1M |
| SG&A Expense | $2.0M |
| Operating Income | $-12.1M |
| Operating Margin | — |
| Interest Expense | $957.0K |
| Pretax Income | — |
| Income Tax Expense | $0 |
| Net Income | $-12.5M |
| Net Margin | — |
| EPS (Basic) | $-3.71 |
| EPS (Diluted) | $-3.71 |
| Shares Outstanding (Basic) | 3.4M |
| Shares Outstanding (Diluted) | 3.4M |
| Dividends Per Share | — |